Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
27,461
archived clinical trials in
Hematology

Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Avon, NY
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Avon, NY
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Batavia, NY
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Batavia, NY
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Bellona, NY
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Bellona, NY
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Canandaigua, NY
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Canandaigua, NY
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Catskill, NY
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Catskill, NY
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Chatham, NY
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Chatham, NY
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Geneva, NY
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Geneva, NY
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Mechanicville, NY
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Mechanicville, NY
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Medina, NY
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Medina, NY
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Palmyra, NY
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Palmyra, NY
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Rochester, NY
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Rochester, NY
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Schenectady, NY
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Schenectady, NY
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Schoharie, NY
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Schoharie, NY
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Troy, NY
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Troy, NY
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Salem, OR
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Salem, OR
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Ashland City, TN
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Ashland City, TN
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Charlotte, TN
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Charlotte, TN
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Chattanooga, TN
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Franklin, TN
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Franklin, TN
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Gallatin, TN
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Gallatin, TN
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Knoxville, TN
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Knoxville, TN
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Lebanon, TN
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Lebanon, TN
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Memphis, TN
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Memphis, TN
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Murfreesboro, TN
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Murfreesboro, TN
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Nashville, TN
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Springfield, TN
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Springfield, TN
Click here to add this to my saved trials
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated:  2/5/2018
Clinical Research Facility
mi
from
Saint Paul, MN
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines
Status: Enrolling
Updated: 2/5/2018
Clinical Research Facility
mi
from
Saint Paul, MN
Click here to add this to my saved trials
Study of Vosaroxin and Decitabine in Older Patients With Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome
A Phase I/II Study of Vosaroxin and Decitabine in Older Patients With Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome
Status: Enrolling
Updated:  2/5/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Study of Vosaroxin and Decitabine in Older Patients With Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome
A Phase I/II Study of Vosaroxin and Decitabine in Older Patients With Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome
Status: Enrolling
Updated: 2/5/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies
Phase I/Ib Study of Azacitidine or Decitabine With Hedgehog Pathway Inhibition in Myeloid Malignancies
Status: Enrolling
Updated:  2/5/2018
The Mayo Clinic
mi
from
Rochester, MN
Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies
Phase I/Ib Study of Azacitidine or Decitabine With Hedgehog Pathway Inhibition in Myeloid Malignancies
Status: Enrolling
Updated: 2/5/2018
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Added to the Combination of Bortezomib and Dexamethasone in Multiple Myeloma Patients
Status: Enrolling
Updated:  2/6/2018
Clinical Research Facility
mi
from
Aurora, CO
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Added to the Combination of Bortezomib and Dexamethasone in Multiple Myeloma Patients
Status: Enrolling
Updated: 2/6/2018
Clinical Research Facility
mi
from
Aurora, CO
Click here to add this to my saved trials
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Added to the Combination of Bortezomib and Dexamethasone in Multiple Myeloma Patients
Status: Enrolling
Updated:  2/6/2018
Clinical Research Facility
mi
from
Baltimore, MD
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Added to the Combination of Bortezomib and Dexamethasone in Multiple Myeloma Patients
Status: Enrolling
Updated: 2/6/2018
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Added to the Combination of Bortezomib and Dexamethasone in Multiple Myeloma Patients
Status: Enrolling
Updated:  2/6/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Added to the Combination of Bortezomib and Dexamethasone in Multiple Myeloma Patients
Status: Enrolling
Updated: 2/6/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Added to the Combination of Bortezomib and Dexamethasone in Multiple Myeloma Patients
Status: Enrolling
Updated:  2/6/2018
Clinical Research Facility
mi
from
Portland, OR
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Added to the Combination of Bortezomib and Dexamethasone in Multiple Myeloma Patients
Status: Enrolling
Updated: 2/6/2018
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Added to the Combination of Bortezomib and Dexamethasone in Multiple Myeloma Patients
Status: Enrolling
Updated:  2/6/2018
Clinical Research Facility
mi
from
Dallas, TX
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Added to the Combination of Bortezomib and Dexamethasone in Multiple Myeloma Patients
Status: Enrolling
Updated: 2/6/2018
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Added to the Combination of Bortezomib and Dexamethasone in Multiple Myeloma Patients
Status: Enrolling
Updated:  2/6/2018
Clinical Research Facility
mi
from
Seattle, WA
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Added to the Combination of Bortezomib and Dexamethasone in Multiple Myeloma Patients
Status: Enrolling
Updated: 2/6/2018
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Added to the Combination of Bortezomib and Dexamethasone in Multiple Myeloma Patients
Status: Enrolling
Updated:  2/6/2018
Clinical Research Facility
mi
from
Milwaukee, WI
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Added to the Combination of Bortezomib and Dexamethasone in Multiple Myeloma Patients
Status: Enrolling
Updated: 2/6/2018
Clinical Research Facility
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Added to the Combination of Bortezomib and Dexamethasone in Multiple Myeloma Patients
Status: Enrolling
Updated:  2/6/2018
Clinical Research Facility
mi
from
La Verne, CA
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Added to the Combination of Bortezomib and Dexamethasone in Multiple Myeloma Patients
Status: Enrolling
Updated: 2/6/2018
Clinical Research Facility
mi
from
La Verne, CA
Click here to add this to my saved trials
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Added to the Combination of Bortezomib and Dexamethasone in Multiple Myeloma Patients
Status: Enrolling
Updated:  2/6/2018
Clinical Research Facility
mi
from
San Francisco, CA
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Added to the Combination of Bortezomib and Dexamethasone in Multiple Myeloma Patients
Status: Enrolling
Updated: 2/6/2018
Clinical Research Facility
mi
from
San Francisco, CA
Click here to add this to my saved trials
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Added to the Combination of Bortezomib and Dexamethasone in Multiple Myeloma Patients
Status: Enrolling
Updated:  2/6/2018
mi
from
San Pablo, CA
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Added to the Combination of Bortezomib and Dexamethasone in Multiple Myeloma Patients
Status: Enrolling
Updated: 2/6/2018
mi
from
San Pablo, CA
Click here to add this to my saved trials
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Added to the Combination of Bortezomib and Dexamethasone in Multiple Myeloma Patients
Status: Enrolling
Updated:  2/6/2018
Clinical Research Facility
mi
from
Boulder, CO
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Added to the Combination of Bortezomib and Dexamethasone in Multiple Myeloma Patients
Status: Enrolling
Updated: 2/6/2018
Clinical Research Facility
mi
from
Boulder, CO
Click here to add this to my saved trials
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Added to the Combination of Bortezomib and Dexamethasone in Multiple Myeloma Patients
Status: Enrolling
Updated:  2/6/2018
Clinical Research Facility
mi
from
Colorado Springs, CO
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Added to the Combination of Bortezomib and Dexamethasone in Multiple Myeloma Patients
Status: Enrolling
Updated: 2/6/2018
Clinical Research Facility
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Added to the Combination of Bortezomib and Dexamethasone in Multiple Myeloma Patients
Status: Enrolling
Updated:  2/6/2018
Clinical Research Facility
mi
from
Denver, CO
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Added to the Combination of Bortezomib and Dexamethasone in Multiple Myeloma Patients
Status: Enrolling
Updated: 2/6/2018
Clinical Research Facility
mi
from
Denver, CO
Click here to add this to my saved trials
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Added to the Combination of Bortezomib and Dexamethasone in Multiple Myeloma Patients
Status: Enrolling
Updated:  2/6/2018
Clinical Research Facility
mi
from
Lakewood, CO
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Added to the Combination of Bortezomib and Dexamethasone in Multiple Myeloma Patients
Status: Enrolling
Updated: 2/6/2018
Clinical Research Facility
mi
from
Lakewood, CO
Click here to add this to my saved trials
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Added to the Combination of Bortezomib and Dexamethasone in Multiple Myeloma Patients
Status: Enrolling
Updated:  2/6/2018
Clinical Research Facility
mi
from
Littleton, CO
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Added to the Combination of Bortezomib and Dexamethasone in Multiple Myeloma Patients
Status: Enrolling
Updated: 2/6/2018
Clinical Research Facility
mi
from
Littleton, CO
Click here to add this to my saved trials
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Added to the Combination of Bortezomib and Dexamethasone in Multiple Myeloma Patients
Status: Enrolling
Updated:  2/6/2018
Clinical Research Facility
mi
from
Longmont, CO
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Added to the Combination of Bortezomib and Dexamethasone in Multiple Myeloma Patients
Status: Enrolling
Updated: 2/6/2018
Clinical Research Facility
mi
from
Longmont, CO
Click here to add this to my saved trials
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Added to the Combination of Bortezomib and Dexamethasone in Multiple Myeloma Patients
Status: Enrolling
Updated:  2/6/2018
Clinical Research Facility
mi
from
Parker, CO
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Added to the Combination of Bortezomib and Dexamethasone in Multiple Myeloma Patients
Status: Enrolling
Updated: 2/6/2018
Clinical Research Facility
mi
from
Parker, CO
Click here to add this to my saved trials
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Added to the Combination of Bortezomib and Dexamethasone in Multiple Myeloma Patients
Status: Enrolling
Updated:  2/6/2018
Clinical Research Facility
mi
from
Pueblo, CO
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Added to the Combination of Bortezomib and Dexamethasone in Multiple Myeloma Patients
Status: Enrolling
Updated: 2/6/2018
Clinical Research Facility
mi
from
Pueblo, CO
Click here to add this to my saved trials
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Added to the Combination of Bortezomib and Dexamethasone in Multiple Myeloma Patients
Status: Enrolling
Updated:  2/6/2018
Clinical Research Facility
mi
from
Thornton, CO
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Added to the Combination of Bortezomib and Dexamethasone in Multiple Myeloma Patients
Status: Enrolling
Updated: 2/6/2018
Clinical Research Facility
mi
from
Thornton, CO
Click here to add this to my saved trials
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Added to the Combination of Bortezomib and Dexamethasone in Multiple Myeloma Patients
Status: Enrolling
Updated:  2/6/2018
Clinical Research Facility
mi
from
Niles, IL
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Added to the Combination of Bortezomib and Dexamethasone in Multiple Myeloma Patients
Status: Enrolling
Updated: 2/6/2018
Clinical Research Facility
mi
from
Niles, IL
Click here to add this to my saved trials
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Added to the Combination of Bortezomib and Dexamethasone in Multiple Myeloma Patients
Status: Enrolling
Updated:  2/6/2018
Clinical Research Facility
mi
from
Winfield, IL
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Added to the Combination of Bortezomib and Dexamethasone in Multiple Myeloma Patients
Status: Enrolling
Updated: 2/6/2018
Clinical Research Facility
mi
from
Winfield, IL
Click here to add this to my saved trials